ZA941176B - Cognition-enhancing selective adenosine receptor agents - Google Patents
Cognition-enhancing selective adenosine receptor agentsInfo
- Publication number
- ZA941176B ZA941176B ZA941176A ZA941176A ZA941176B ZA 941176 B ZA941176 B ZA 941176B ZA 941176 A ZA941176 A ZA 941176A ZA 941176 A ZA941176 A ZA 941176A ZA 941176 B ZA941176 B ZA 941176B
- Authority
- ZA
- South Africa
- Prior art keywords
- cognition
- adenosine receptor
- pct
- selective adenosine
- receptor agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2350193A | 1993-02-26 | 1993-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA941176B true ZA941176B (en) | 1994-09-20 |
Family
ID=21815459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA941176A ZA941176B (en) | 1993-02-26 | 1994-02-21 | Cognition-enhancing selective adenosine receptor agents |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5840729A (enExample) |
| EP (1) | EP0686155B1 (enExample) |
| JP (1) | JPH08512281A (enExample) |
| KR (1) | KR100315898B1 (enExample) |
| CN (1) | CN1041418C (enExample) |
| AT (1) | ATE169019T1 (enExample) |
| AU (1) | AU680241B2 (enExample) |
| CA (1) | CA2155130C (enExample) |
| DE (1) | DE69412073T2 (enExample) |
| DK (1) | DK0686155T3 (enExample) |
| ES (1) | ES2120025T3 (enExample) |
| HU (1) | HUT72677A (enExample) |
| IL (1) | IL108750A (enExample) |
| MX (1) | MX9401406A (enExample) |
| NO (1) | NO311920B1 (enExample) |
| NZ (1) | NZ262984A (enExample) |
| TW (1) | TW261532B (enExample) |
| WO (1) | WO1994019349A1 (enExample) |
| ZA (1) | ZA941176B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0972525A4 (en) * | 1997-03-18 | 2000-11-29 | Fujisawa Pharmaceutical Co | PREVENTIVE AND HEALING AGENTS AGAINST HYPERPHOSPHATEMIA |
| HUP0103836A3 (en) | 1998-06-02 | 2003-05-28 | Osi Pharmaceuticals Inc Uniond | Pyrrolo[2,3d]pyrimidine compositions and their use |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| JP2005529062A (ja) | 2001-11-30 | 2005-09-29 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アデノシンａ１及びａ３受容体に特異的な化合物とその使用 |
| KR20040068317A (ko) | 2001-12-20 | 2004-07-30 | 오에스아이 파마슈티컬스, 인코포레이티드 | 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도 |
| US6903220B2 (en) * | 2002-05-15 | 2005-06-07 | Genzyme Corporation | Synthesis of chiral 2-alkyl amino acids |
| WO2004086047A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) |
| KR20060124615A (ko) * | 2003-12-09 | 2006-12-05 | 교와 핫꼬 고교 가부시끼가이샤 | 고차 뇌기능 장애의 예방 및/또는 치료제 |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| JPH0455150A (ja) * | 1990-06-22 | 1992-02-21 | Takata Kk | 助手席用エアバッグ装置 |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1994
- 1994-01-27 CA CA002155130A patent/CA2155130C/en not_active Expired - Fee Related
- 1994-01-27 DK DK94910661T patent/DK0686155T3/da active
- 1994-01-27 DE DE69412073T patent/DE69412073T2/de not_active Expired - Fee Related
- 1994-01-27 AU AU62968/94A patent/AU680241B2/en not_active Ceased
- 1994-01-27 HU HU9502495A patent/HUT72677A/hu unknown
- 1994-01-27 US US08/500,991 patent/US5840729A/en not_active Expired - Fee Related
- 1994-01-27 JP JP6518986A patent/JPH08512281A/ja active Pending
- 1994-01-27 CN CN94191309A patent/CN1041418C/zh not_active Expired - Fee Related
- 1994-01-27 ES ES94910661T patent/ES2120025T3/es not_active Expired - Lifetime
- 1994-01-27 NZ NZ262984A patent/NZ262984A/en unknown
- 1994-01-27 EP EP94910661A patent/EP0686155B1/en not_active Expired - Lifetime
- 1994-01-27 KR KR1019950703577A patent/KR100315898B1/ko not_active Expired - Fee Related
- 1994-01-27 AT AT94910661T patent/ATE169019T1/de not_active IP Right Cessation
- 1994-01-27 WO PCT/US1994/001009 patent/WO1994019349A1/en not_active Ceased
- 1994-02-21 ZA ZA941176A patent/ZA941176B/xx unknown
- 1994-02-22 TW TW083101485A patent/TW261532B/zh active
- 1994-02-23 IL IL10875094A patent/IL108750A/xx not_active IP Right Cessation
- 1994-02-24 MX MX9401406A patent/MX9401406A/es not_active IP Right Cessation
-
1995
- 1995-08-25 NO NO19953353A patent/NO311920B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69412073D1 (de) | 1998-09-03 |
| JPH08512281A (ja) | 1996-12-24 |
| AU680241B2 (en) | 1997-07-24 |
| DK0686155T3 (da) | 1999-02-01 |
| IL108750A (en) | 2000-09-28 |
| CN1118599A (zh) | 1996-03-13 |
| IL108750A0 (en) | 1994-05-30 |
| DE69412073T2 (de) | 1999-02-18 |
| CA2155130C (en) | 1994-09-01 |
| EP0686155A1 (en) | 1995-12-13 |
| ES2120025T3 (es) | 1998-10-16 |
| ATE169019T1 (de) | 1998-08-15 |
| NO953353D0 (no) | 1995-08-25 |
| MX9401406A (es) | 1994-08-31 |
| NO953353L (no) | 1995-08-25 |
| EP0686155B1 (en) | 1998-07-29 |
| TW261532B (enExample) | 1995-11-01 |
| CA2155130A1 (en) | 1994-09-01 |
| NO311920B1 (no) | 2002-02-18 |
| NZ262984A (en) | 1997-05-26 |
| WO1994019349A1 (en) | 1994-09-01 |
| AU6296894A (en) | 1994-09-14 |
| HUT72677A (en) | 1996-05-28 |
| HU9502495D0 (en) | 1995-10-30 |
| US5840729A (en) | 1998-11-24 |
| KR100315898B1 (ko) | 2002-02-28 |
| CN1041418C (zh) | 1998-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL117848A0 (en) | Novel compounds a process for their production and pharmacetical compositions containing same | |
| NO952229D0 (no) | Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader | |
| DE69611377D1 (de) | 1,2,4-triazolo[1,5-c]pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor | |
| CA2094716A1 (en) | Back support for a chair or seat | |
| GB9317104D0 (en) | Therapeutic heterocycles | |
| EP0509019A4 (en) | Treatment of human retroviral infections with 2',3'-dideoxyinosine | |
| TW261513B (enExample) | ||
| HU9502065D0 (en) | Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes | |
| TW283647B (enExample) | ||
| IL108750A0 (en) | Cognition-enhancing selective adenosine receptor agents | |
| GR3025698T3 (en) | NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES. | |
| DE68918944D1 (de) | Künstliche rezeptor-analoge. | |
| DE3879535D1 (enExample) | ||
| GR3033611T3 (en) | Process of conjugation of antiviral nucleosides with lactosaminated human albumin. | |
| GB9507883D0 (en) | Compounds | |
| SE9404438D0 (sv) | New process | |
| IL104817A0 (en) | Sugar derivatives of macrolides | |
| IL107917A0 (en) | Triazoloquinazolines, their preparation and their use as medicaments | |
| 胡金生 | Acupuncture Treatment of Dizziness and Vertigo | |
| HU9500709D0 (en) | Optically active hydroquinine (amino-3-phenyl)-1-ethanesulfonate, preparation and use thereof | |
| PL322847A1 (en) | Condensed b-carbolins | |
| TW288005B (enExample) | ||
| GR3027682T3 (en) | 4-guanidinobutyramide for improving blood circulation. |